| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 30 | 2020 | 211 | 9.560 |
Why?
|
| Geriatric Assessment | 35 | 2020 | 335 | 8.000 |
Why?
|
| Neoplasms | 37 | 2020 | 754 | 4.000 |
Why?
|
| Geriatrics | 12 | 2019 | 86 | 3.210 |
Why?
|
| Medical Oncology | 14 | 2020 | 90 | 2.530 |
Why?
|
| Hematologic Neoplasms | 6 | 2020 | 39 | 2.420 |
Why?
|
| Aged | 85 | 2020 | 10260 | 2.380 |
Why?
|
| Antineoplastic Agents | 16 | 2020 | 595 | 2.090 |
Why?
|
| Quality of Health Care | 3 | 2019 | 148 | 1.700 |
Why?
|
| Aged, 80 and over | 42 | 2020 | 3898 | 1.590 |
Why?
|
| Humans | 104 | 2020 | 32274 | 1.580 |
Why?
|
| Comorbidity | 19 | 2018 | 565 | 1.330 |
Why?
|
| Age Factors | 25 | 2020 | 1179 | 1.260 |
Why?
|
| Breast Neoplasms | 9 | 2020 | 762 | 1.250 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2020 | 25 | 1.180 |
Why?
|
| Quality of Life | 16 | 2019 | 964 | 1.170 |
Why?
|
| Activities of Daily Living | 10 | 2019 | 245 | 1.150 |
Why?
|
| Aging | 9 | 2019 | 942 | 1.130 |
Why?
|
| Cognition | 7 | 2018 | 547 | 1.000 |
Why?
|
| Female | 62 | 2020 | 19942 | 0.990 |
Why?
|
| Hematology | 4 | 2020 | 8 | 0.950 |
Why?
|
| Anthracyclines | 4 | 2020 | 52 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 443 | 0.910 |
Why?
|
| Disease Management | 4 | 2019 | 129 | 0.850 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 312 | 0.830 |
Why?
|
| Male | 53 | 2020 | 19437 | 0.820 |
Why?
|
| Mobility Limitation | 3 | 2020 | 208 | 0.820 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2020 | 187 | 0.810 |
Why?
|
| Treatment Outcome | 15 | 2019 | 3416 | 0.750 |
Why?
|
| Polypharmacy | 4 | 2018 | 17 | 0.750 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 212 | 0.740 |
Why?
|
| Accidental Falls | 3 | 2020 | 104 | 0.710 |
Why?
|
| Hematologic Diseases | 2 | 2018 | 20 | 0.680 |
Why?
|
| Prospective Studies | 20 | 2020 | 2316 | 0.660 |
Why?
|
| Self-Help Devices | 1 | 2020 | 6 | 0.660 |
Why?
|
| Middle Aged | 29 | 2020 | 11848 | 0.650 |
Why?
|
| Prognosis | 11 | 2020 | 1534 | 0.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 108 | 0.610 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 51 | 0.610 |
Why?
|
| Hyperglycemia | 2 | 2018 | 85 | 0.590 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2020 | 105 | 0.590 |
Why?
|
| Depression | 4 | 2018 | 420 | 0.580 |
Why?
|
| Carboplatin | 2 | 2018 | 42 | 0.580 |
Why?
|
| Paclitaxel | 1 | 2018 | 57 | 0.550 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 100 | 0.550 |
Why?
|
| Survival Rate | 8 | 2020 | 893 | 0.520 |
Why?
|
| Health Services for the Aged | 2 | 2015 | 24 | 0.510 |
Why?
|
| Hospitalization | 4 | 2018 | 475 | 0.510 |
Why?
|
| Risk Assessment | 5 | 2018 | 1425 | 0.510 |
Why?
|
| Patient Care Management | 1 | 2016 | 19 | 0.500 |
Why?
|
| Physician's Role | 1 | 2016 | 41 | 0.490 |
Why?
|
| Blood Glucose | 1 | 2018 | 484 | 0.490 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 555 | 0.490 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 24 | 0.480 |
Why?
|
| Cognition Disorders | 3 | 2015 | 349 | 0.480 |
Why?
|
| Stroke Volume | 4 | 2020 | 417 | 0.450 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 773 | 0.450 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 423 | 0.440 |
Why?
|
| Risk Factors | 13 | 2020 | 3934 | 0.410 |
Why?
|
| Physical Fitness | 1 | 2014 | 120 | 0.410 |
Why?
|
| Decision Making | 4 | 2020 | 189 | 0.410 |
Why?
|
| Social Support | 5 | 2019 | 180 | 0.400 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 1158 | 0.400 |
Why?
|
| Tamoxifen | 1 | 2013 | 59 | 0.400 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 131 | 0.390 |
Why?
|
| Disability Evaluation | 5 | 2020 | 242 | 0.380 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 68 | 0.370 |
Why?
|
| Longitudinal Studies | 9 | 2019 | 757 | 0.370 |
Why?
|
| United States | 14 | 2020 | 4072 | 0.370 |
Why?
|
| Exercise | 5 | 2019 | 603 | 0.370 |
Why?
|
| Hand Strength | 3 | 2020 | 98 | 0.360 |
Why?
|
| Medication Adherence | 1 | 2013 | 160 | 0.350 |
Why?
|
| Body Composition | 4 | 2020 | 327 | 0.340 |
Why?
|
| Exercise Therapy | 1 | 2013 | 250 | 0.330 |
Why?
|
| Retrospective Studies | 10 | 2018 | 3624 | 0.320 |
Why?
|
| Walking | 2 | 2010 | 200 | 0.300 |
Why?
|
| Anemia | 3 | 2020 | 50 | 0.300 |
Why?
|
| Survivors | 3 | 2016 | 173 | 0.300 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 651 | 0.280 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 98 | 0.280 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 95 | 0.280 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 324 | 0.280 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 180 | 0.270 |
Why?
|
| Logistic Models | 5 | 2020 | 743 | 0.260 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 1479 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 541 | 0.260 |
Why?
|
| Colorectal Neoplasms | 3 | 2015 | 219 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1437 | 0.260 |
Why?
|
| Nutritional Status | 2 | 2020 | 73 | 0.260 |
Why?
|
| Adult | 13 | 2020 | 9256 | 0.250 |
Why?
|
| Ventricular Function, Left | 2 | 2020 | 264 | 0.250 |
Why?
|
| Heart Ventricles | 2 | 2018 | 146 | 0.250 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 489 | 0.240 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2005 | 2 | 0.240 |
Why?
|
| Nasal Cavity | 1 | 2005 | 6 | 0.240 |
Why?
|
| Nose Neoplasms | 1 | 2005 | 4 | 0.240 |
Why?
|
| Curriculum | 2 | 2017 | 203 | 0.230 |
Why?
|
| Consensus | 3 | 2020 | 87 | 0.220 |
Why?
|
| Mental Health | 2 | 2016 | 111 | 0.220 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 221 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 395 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2019 | 1840 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2020 | 477 | 0.200 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 179 | 0.190 |
Why?
|
| Independent Living | 2 | 2020 | 90 | 0.190 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 231 | 0.190 |
Why?
|
| Nutrition Assessment | 2 | 2016 | 48 | 0.190 |
Why?
|
| Hemoglobins | 2 | 2020 | 45 | 0.190 |
Why?
|
| Radiotherapy, Conformal | 1 | 2011 | 18 | 0.180 |
Why?
|
| Patient Preference | 2 | 2020 | 48 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 52 | 0.170 |
Why?
|
| SEER Program | 2 | 2019 | 38 | 0.170 |
Why?
|
| Motor Activity | 2 | 2013 | 332 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2020 | 60 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2017 | 69 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2018 | 153 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2020 | 69 | 0.160 |
Why?
|
| Inpatients | 2 | 2018 | 83 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 194 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2020 | 50 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2020 | 109 | 0.150 |
Why?
|
| Risk | 3 | 2016 | 305 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 68 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2020 | 179 | 0.150 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 461 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2018 | 168 | 0.150 |
Why?
|
| Muscle Strength | 1 | 2020 | 135 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 98 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2019 | 184 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 219 | 0.140 |
Why?
|
| Behavioral Symptoms | 1 | 2018 | 3 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 114 | 0.140 |
Why?
|
| Research Design | 2 | 2020 | 314 | 0.140 |
Why?
|
| Vision Disorders | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hearing Loss | 1 | 2018 | 25 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 20 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 158 | 0.140 |
Why?
|
| Fluorouracil | 2 | 2017 | 79 | 0.140 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2015 | 135 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.130 |
Why?
|
| Mastectomy | 1 | 2017 | 59 | 0.130 |
Why?
|
| Exercise Movement Techniques | 1 | 2016 | 2 | 0.130 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 4 | 0.130 |
Why?
|
| Career Mobility | 1 | 2017 | 17 | 0.130 |
Why?
|
| Leukemia | 1 | 2017 | 38 | 0.130 |
Why?
|
| Education | 1 | 2016 | 31 | 0.130 |
Why?
|
| Diet | 1 | 2019 | 383 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2017 | 121 | 0.120 |
Why?
|
| Medicine | 1 | 2017 | 36 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 24 | 0.120 |
Why?
|
| Nutrition Disorders | 1 | 2016 | 10 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 158 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2240 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 86 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2016 | 16 | 0.120 |
Why?
|
| Research | 1 | 2016 | 81 | 0.120 |
Why?
|
| Time Factors | 4 | 2017 | 2204 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 390 | 0.110 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1076 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2016 | 204 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 6 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 178 | 0.110 |
Why?
|
| North Carolina | 3 | 2018 | 1300 | 0.110 |
Why?
|
| Medicaid | 2 | 2012 | 101 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 42 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 297 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2017 | 330 | 0.110 |
Why?
|
| Women's Health | 1 | 2016 | 230 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2014 | 57 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2016 | 243 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 273 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2012 | 308 | 0.100 |
Why?
|
| Portraits as Topic | 1 | 2013 | 4 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 26 | 0.100 |
Why?
|
| Azacitidine | 1 | 2013 | 27 | 0.100 |
Why?
|
| CA-125 Antigen | 1 | 2013 | 8 | 0.100 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2013 | 6 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 883 | 0.100 |
Why?
|
| Prevalence | 4 | 2018 | 955 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2013 | 15 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 8 | 0.100 |
Why?
|
| Anxiety | 1 | 2014 | 190 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 19 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 73 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 327 | 0.090 |
Why?
|
| African Americans | 1 | 2019 | 1335 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 144 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 84 | 0.090 |
Why?
|
| Adiposity | 1 | 2013 | 190 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 242 | 0.090 |
Why?
|
| Inflammation | 1 | 2015 | 506 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 45 | 0.090 |
Why?
|
| Nonprescription Drugs | 1 | 2012 | 18 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 427 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2012 | 27 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2011 | 12 | 0.090 |
Why?
|
| Postmenopause | 1 | 2013 | 424 | 0.090 |
Why?
|
| Heart Failure | 1 | 2018 | 728 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2012 | 80 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 86 | 0.080 |
Why?
|
| Extremities | 1 | 2011 | 54 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 70 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 188 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2020 | 863 | 0.080 |
Why?
|
| Poverty | 1 | 2011 | 105 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 256 | 0.080 |
Why?
|
| Sarcoma | 1 | 2011 | 92 | 0.080 |
Why?
|
| Mass Screening | 1 | 2012 | 256 | 0.080 |
Why?
|
| Disabled Persons | 1 | 2010 | 100 | 0.070 |
Why?
|
| Heart Failure, Diastolic | 1 | 2009 | 15 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 907 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2009 | 69 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1111 | 0.070 |
Why?
|
| Mentors | 1 | 2008 | 33 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 116 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2008 | 76 | 0.070 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 100 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 536 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 490 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 534 | 0.050 |
Why?
|
| Remission Induction | 2 | 2015 | 92 | 0.050 |
Why?
|
| Linear Models | 2 | 2015 | 425 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 2648 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1241 | 0.040 |
Why?
|
| Blood Donors | 1 | 2020 | 11 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 14 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2020 | 35 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 44 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2020 | 80 | 0.040 |
Why?
|
| Tennessee | 1 | 2020 | 98 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 116 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 238 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 63 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 56 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 167 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 34 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 456 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 388 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 144 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 76 | 0.030 |
Why?
|
| Vomiting | 1 | 2018 | 19 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2018 | 14 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 154 | 0.030 |
Why?
|
| Nausea | 1 | 2018 | 49 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 69 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 90 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 211 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 854 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 48 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 78 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 25 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 63 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 11 | 0.030 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 19 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 30 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 292 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 24 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2017 | 41 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 62 | 0.030 |
Why?
|
| Sulfides | 1 | 2017 | 27 | 0.030 |
Why?
|
| Caprylates | 1 | 2017 | 27 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.030 |
Why?
|
| Camptothecin | 1 | 2017 | 45 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 139 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mind-Body Therapies | 1 | 2016 | 10 | 0.030 |
Why?
|
| Creatine | 1 | 2016 | 5 | 0.030 |
Why?
|
| Life Style | 1 | 2019 | 393 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 98 | 0.030 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2016 | 8 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 101 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 20 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 99 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 302 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 164 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 175 | 0.030 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2015 | 20 | 0.030 |
Why?
|
| DNA Helicases | 1 | 1995 | 4 | 0.030 |
Why?
|
| Cytarabine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 23 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 287 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1995 | 34 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2015 | 159 | 0.030 |
Why?
|
| DNA Repair | 1 | 1995 | 55 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 323 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 717 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 224 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 272 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1995 | 88 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 227 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 276 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 215 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 285 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 149 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 413 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 355 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 15 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 25 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 98 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 591 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 52 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 90 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 316 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 78 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 146 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 3517 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2009 | 34 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 853 | 0.010 |
Why?
|
| Conjugation, Genetic | 1 | 1995 | 1 | 0.010 |
Why?
|
| RecQ Helicases | 1 | 1995 | 1 | 0.010 |
Why?
|
| Methyl Methanesulfonate | 1 | 1995 | 4 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1995 | 14 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1995 | 38 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1995 | 17 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1995 | 48 | 0.010 |
Why?
|